Physician profile
Subir Jossan
NPI 1922006808
$1,166.31
in general payments reported to CMS, 2019-2025
13 companies · $252 in 2025
The $252 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $136 · 2021: $101 · 2022: $36.61 · 2023: $168 · 2024: $48.85 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $157.33 | 2019 | |
| Supreme Orthopedic Systems, LLC | $151.76 | 2025 | |
| Medartis INC. | $148.32 | 2019-2023 | Aptus |
| Orthofix Medical, INC. | $141.26 | 2021-2025 | Physio-Stim |
| Endo Pharmaceuticals INC. | $131.13 | 2019-2023 | Xiaflex |
| Depuy Synthes Sales INC. | $116.99 | 2019 | |
| Osteomed LLC | $94.48 | 2020 | |
| Checkpoint Surgical, INC | $71.87 | 2023 | Checkpoint Stimulators |
| Innovation Technologies INC | $58.94 | 2021-2022 | |
| Stryker Corporation | $27.48 | 2019 | |
| Endo USA, INC. | $25.86 | 2024 | Xiaflex |
| Axogen | $22.99 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Cap |
| Horizon Therapeutics Plc | $17.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subir Jossan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.